These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16794543)

  • 1. Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin.
    Gondolesi G; Blondeau B; Maurette R; Hoppenhauer L; Rodriguez-Laiz G; Schiano T; Boros P; Bromberg J; Akalin E; Sauter B
    Transplantation; 2006 Jun; 81(12):1743-6. PubMed ID: 16794543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Desensitization protocols in immunized living donor kidney transplant recipients].
    Nocera A
    G Ital Nefrol; 2009; 26(4):499-515. PubMed ID: 19644839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
    Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
    Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
    Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG
    Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization: achieving immune detente.
    Zachary AA; Eng HS
    Tissue Antigens; 2011 Jan; 77(1):3-8. PubMed ID: 21155718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience.
    Jordan SC; Vo AA; Nast CC; Tyan D
    Clin Transpl; 2003; ():193-8. PubMed ID: 15387111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients.
    Duronio A; Bajjoka I; Hsaiky L; Parasuraman R
    Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates.
    Taber T; Mujtaba MA; Goggins W; Higgins N; Sharfuddin A; Yaqub MS; Mishler D; Book B; Chen J; Lobashevsky A
    Clin Transplant; 2013; 27(4):E375-82. PubMed ID: 23721524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation.
    Ikegami T; Taketomi A; Soejima Y; Yoshizumi T; Uchiyama H; Harada N; Iguchi T; Hashimoto N; Maehara Y
    Transplantation; 2009 Aug; 88(3):303-7. PubMed ID: 19667930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience.
    Magee CC; Felgueiras J; Tinckam K; Malek S; Mah H; Tullius S
    Transplantation; 2008 Jul; 86(1):96-103. PubMed ID: 18622284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients.
    Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA
    Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible?
    Faenza A; Fuga G; Bertelli R; Scolari MP; Buscaroli A; Stefoni S
    Transplant Proc; 2008; 40(6):1833-8. PubMed ID: 18675064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications.
    Jordan S; Cunningham-Rundles C; McEwan R
    Am J Transplant; 2003 Jun; 3(6):653-64. PubMed ID: 12780556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
    Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
    J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch.
    Wright EJ; Fiser WP; Edens RE; Frazier EA; Morrow WR; Imamura M; Jaquiss RD
    J Heart Lung Transplant; 2007 Nov; 26(11):1163-9. PubMed ID: 18022083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.